

| Drug common name | Satraplatin |
| INN | satraplatin |
| Description | Satraplatin (INN, codenamed JM216) is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.
|
| Classification | Small molecule |
| Drug class | antineoplastics (platinum derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | 129580-63-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3833367 |
| ChEBI ID | — |
| PubChem CID | 6918220 |
| DrugBank | — |
| UNII ID | 8D7B37T28G (ChemIDplus, GSRS) |
